Endotracheal mechanical ventilation (EMV) in preterm infants has been linked with various forms of lung injury including bronchopulmonary dysplasia, infections, and air leak syndromes-collectively termed ventilator-induced lung injury (VILI). [1] [2] [3] As such, there has been a trend of increasing use of noninvasive ventilation (NIV) modes in neonatal intensive care units (NICUs) over the last decade in an attempt to reduce VILI, [4] [5] [6] with recent reports demonstrating equal effectiveness of NIV when compared with EMV in preterm infants.
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Various forms of NIV are available for use in clinical practice including nasal continuous positive airway pressure (NCPAP), biphasic NCPAP (BP-NCPAP), and noninvasive intermittent positive airway pressure (NIPPV). 5 Many studies comparing these different modes of NIV have yielded inconsistent results with regards to effectiveness in preventing reintubation, [9] [10] [11] [12] and the choice of the mode of NIV used is largely based on local practices and comfort. 4 In recent years, reported a failure rate of approximately 40% within 1 week of extubation in a cohort of infants less than 1,000 g. 14 Similarly,
Barrington et al reported a failure rate of 44% within 72 hours in a cohort of infants less than 1,251 g. 9 As such, to minimize the risk of EMV and VILI, a relatively newer form of NIV that is emerging is noninvasive high-frequency ventilation (NIHFV). In this modality, high-frequency ventilation is delivered via nasopharyngeal tubes, short nasal prongs or masks. While this modality holds promise, there are only a limited number of clinical studies evaluating it in the neonatal population, as described later.
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To date, the clinical use of NIHFV has only been evaluated in four studies. Two small case series studies on 21 and 14 infants reported a decrease in carbon dioxide (CO 2 ) with NIHFV use. Over the last few years, with the goal of minimizing EMV, NIHFV has gained acceptance for use in a select group of highrisk patients at our centers based on positive experience at one European institution in Cologne, Germany (Dr. André Oberthür, MD; written communication, September 16, 2010) . However, there is still very limited data on its effectiveness, indications for use, and safety profile. We conducted a retrospective review of the experience with the use of NIHFV at our centers, with the goal of addressing these specific questions. We hypothesized that the use of NIHFV will be associated with successful sustained extubation in a significant proportion of high-risk patients placed on this mode, while reducing the number of apneas, bradycardias, and desaturations as well as improving both oxygenation and ventilation.
Methods

Research Design
This was a retrospective case series study conducted at four large Canadian tertiary care NICUs. All infants who were placed on NIHFV at these centers between July 2010 (time when NIHFV use was adopted) and September 2012 were included.
Data Collection
Data were collected from health records of all patients on NIHFV by two authors (A.M. and B.S.) using a standardized data collection form. At each site, log files kept by respiratory therapists for all patients trialed on NIHFV were reviewed. Data were collected on baseline characteristics of each "instance" including sex, birth gestational age and weight, as well as age (in days), postmenstrual age (PMA), and weight at time of NIHFV use. Each instance refers to a unique NIHFV trial. If NIHFV was utilized on one patient on three separate occasions, this patient contributed on three instances to all data, including baseline characteristics. Other parameters such as mode of delivery, maternal chorioamnionitis, surfactant administration, use of antenatal steroids (complete defined as two doses, incomplete defined as one dose before delivery), chronic lung disease (defined as supplemental oxygen or respiratory support requirement at 36 weeks' PMA) were also documented. Data collected for NIHFV use included indications and duration of use, all recorded settings, (including mean airway pressure [MAP] , amplitude, and frequency) and the mode of ventilation immediately preceding and following NIHFV initiation. Indication of NIHFV use was divided into "rescue" (when transitioned from another NIV mode) or "prophylactic" (when extubated directly to NIHFV).
Other outcome data collected included number of apneic, bradycardic (heart rate < 100 bpm) or desaturation (oxygen saturation < 85%) episodes denoted collectively as "spells" as per nursing chart records, fraction of inspired oxygen (FiO 2 ), and CO 2 levels as measured transcutaneously (or from a blood gas sample where available) preceding and following NIHFV initiation. Because of the retrospective nature of this study, there were some instances where one or more of these data were not available for analysis. Any documented adverse outcomes attributed to NIHFV use were searched for in each patient's chart. Furthermore, all cranial ultrasonography results preceding and following NIHFV initiation were documented, and intraventricular hemorrhage (IVH) was reported according to the Papile classification.
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Instruments and Devices
NIHFV was administered using either short nasal prongs or masks (BC series, Fisher and Paykel Healthcare, Laval, Québec, Canada) at each participating site. If required due to pressure leak, chinstraps were used at the discretion of the attending medical team. Two sites used the Babylog 8000 (Drager, Lubeck, Germany), one of which also used the Leoni Plus (Heinen þ Lowenstein, Deutschland, Germany) and the remaining two sites used the VN500 (Drager, Lubeck, Germany) to deliver NIHFV. The ventilators were connected to the nasal interface using nonrigid circuits (RT series, Fisher and Paykel Healthcare, Laval, Québec, Canada).
Noninvasive Ventilation Use
The use of NIHFV at each institution was based on locally developed guidelines that provided indications for NIHFV use, initial settings of various parameters and weaning/adjustment strategies. These guidelines were used in addition to clinical judgment of the attending medical team. Supplementary file number 1 (available online only) summarizes the guidelines from each institution. Similarly, each unit also had guidelines for CPAP, BP-NCPAP and NIPPV use-provided as supplementary file number 2 (available online only).
Outcomes
The primary outcome was the rate of successful transition to another mode of NIV without the need for intubation on NIHFV. The decision to intubate a patient was based on the medical team's discretion at each site, with no specific predefined guidelines. Secondary outcomes included a comparison of the mean of the number of spells 6 hours before and 6 hours after NIHFV use. FiO 2 and transcutaneous CO 2 (TcCO2), or PaCO 2 where available, levels immediately before and 1 hour after NIHFV use were also comparatively analyzed. The data for spells was collected for rescue NIHFV use only, as in instances of prophylactic use, the patient was intubated before NIHFV use. Any adverse outcomes attributed to the use of NIHFV were reported, as well as grades of IVH before and after NIHFV use.
Statistical Analysis
All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC). Baseline characteristics were described using descriptive statistics. When comparing outcomes data, t-test, Wilcoxon rank sum test, chi-squared test, or Fisher exact test were used as appropriate. All data are reported as median (range) when describing the baseline characteristics and duration of NIHFV use, or mean (standard deviation [SD]) when describing the secondary outcomes such as spells, oxygenation, and ventilation.
Ethics Review
This study was approved by the research ethics boards of each participating institution.
Results
Patient Characteristics
Over the study period, 52 infants underwent NIHFV at the four study sites and contributed to a total of 79 instances of its use. ►Table 1 depicts the baseline characteristics of all instances of NIHFV use based on the primary outcome. Only the mode of delivery was significantly different between the two groups (p ¼ 0.0170).
Indications and Settings of Noninvasive HighFrequency Ventilation Use
NIHFV was used as a rescue mode in 58 of the 79 instances (73% of all use) and as a prophylactic mode in the remainder. The settings used on NIHFV were highly variable. The ranges for MAP and frequency were 8 to 24 cm H 2 O and 6 to 14 Hz, respectively. The amplitude ranged from 20 to 100% when the Babylog 8000 was used and 20 to 60 cm H 2 O with the use of the VN500.
Outcomes
Of all instances of NIHFV use, 46 (58%) patients were successfully transitioned to another NIV mode, precluding the need for intubation. In the remaining 33 instances (42%), patients required intubation. When all NIHFV instances were stratified by weight at NIHFV initiation (< 1,000 vs. > 1,000 g) or by indication (prophylactic vs. rescue), the rate of successful transition to another NIV remained greater than 50% for all subgroups, as shown in ►Table 2. Amongst those intubated after NIHFV use, the two most common indications were spells (52%) and ventilation failure (42%), as defined by CO 2 retention.
Data for number of spells were available for 49 instances, and the number of spells over 6 hours decreased from 3. No adverse events attributable to NIHFV were reported. Cranial ultrasonography results preceding and following NIHFV initiation were available in 73 instances. There was progression of IVH in two patients-no IVH to unilateral grade II IVH in one, and unilateral grade I to bilateral grade II IVH in the other. In the remaining instances, there was either no change (n ¼ 68) or regression of IVH grades (n ¼ 3). There were no reports of nasal septum injury, necrotizing enterocolitis, or bowel perforations attributed specifically to NIHFV use.
Discussion
In this retrospective analysis of our experience, NIHFV was utilized in 79 instances, and in the majority of cases its use was as a rescue mode. About 58% of all NIHFV instances (rescue or prophylactic) resulted in a successful transition to another NIV mode, thus preventing intubation in the majority of this high-risk patient group. The use of NIHFV was associated with a decrease in the number of "spells", as well as an improvement in oxygenation and ventilation. No adverse events were reported as a result of NIHFV use.
To our knowledge, this is the largest reported case series of patients on NIHFV, and the first to report its use on such a large group of patients at high risk of requiring intubation from North America. These results confirm the feasibility and add to the growing body of literature supporting the use of NIHFV as an effective modality in preventing intubation. Arguably, in many of the cases in our study, patients would have been intubated had it not been for the use of NIHFV. This is particularly evident given that the majority of these patients were already on what is perceived to be maximum NIV support with either BP-NCPAP or NIPPV preceding rescue Previously, a study by van der Hoeven et al demonstrated the use of NIHFV in a heterogeneous patient population (21 preterm and term infants) with NCPAP failure based on either higher PaCO 2 levels, acidosis, or higher FiO 2 requirements and reported a decrease in PaCO 2 levels.
15 NIHFV was used for a median of 35 hours and demonstrated a decrease in the CO 2 levels from 8.3 to 7.2 kPa, with no adverse effects. Although many of the patients remained extubated, many of these infants were term and were unlikely to require intubation in the first place. Colaizy et al studied a group of infants who were stable on NCPAP after putting them on NIHFV for 2 hours, and showed a decrease in TcCO 2 levels in this group of 14 infants. However, it is difficult extrapolate these results to high-risk patient population. 16 Neither of these two studies examined extubation failure rates or change in number of spells. A randomized controlled trial comparing NIHFV with NCPAP in 46 term infants showed a reduction in time to clinical improvement of TTN from 377 to 105 minutes.
17
However, it can be argued that many of these infants did not require NIHFV (or NCPAP) in the first place, and were unlikely to be at high risk of requiring intubation. Furthermore, the unblinded nature of the study inherently introduces biases, and the reported benefit of NIHFV over NCPAP in this context must be interpreted with caution. Czernik et al have reported the prophylactic use of NIHFV in 20 infants after extubation. 18 Of the 20 infants, 14 remained extubated and were transitioned to another NIV mode, after remaining on NIHFV for a minimum of 32 hours. However, although these infants were deemed to be at a high risk of extubation failure, without a control group, it is difficult to predict as to how many infants would have remained extubated even without the use of NIHFV. NIHFV holds promise as a mode of NIV that might help reduce the risk of intubation in a select group of high-risk patients. It may help reduce the number of spells, and improve ventilation as well as oxygenation. An additional advantage conferred by NIHFV may be the lack of the need for synchronization, something that remains a challenge with current use of NIPPV.
5,11 Even though NIHFV was used successfully in preterm infants less than 1,000 g without any reported adverse effects, the safety profile remains unknown, particularly in the extremely preterm infants. To our knowledge, no study has been planned or powered appropriately to address the safety profile specifically. Further work needs to be done to elucidate the group of patients most likely to benefit from this modality, and to adequately address its safety profile. Yet another area of uncertainty is the parameters for use in NIHFV. As noted earlier, there is a significant range of MAPs used, which raises the possibility that it may be the higher recruitment pressure, rather than the oscillatory effect that leads to these improved outcomes. The use of this large range of MAPs also raises the question of what should the appropriate limit be. On the one hand, positive end expiratory pressures with the use of NCPAP rarely exceed 8 to 10 cm H 2 O, 5 whereas similar MAP ranges as reported here in NIHFV are routinely used in intubated patients on high-frequency ventilation.
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Therefore, while seemingly acceptable for intubated patients, it is unclear whether there is an increased risk of harm when such MAPs are administered via noninvasive interfaces. The ventilation tubing and leak at the level of the nasopharynx leads to a much lower delivered MAP and amplitude than that set at the ventilator-however the quantification of this dampening effect is currently unknown and requires further research. Although no cases were identified in the present review, the risk of abdominal distension and associated complications including perforation need to be carefully considered. These questions remain unanswered but with rigorously planned prospective studies to help address them and with further experience with its use, NIHFV has the potential to minimize the long-term morbidities associated with EMV. One of the limitations of the study is the lack of a control group. However, given that the majority of NIHFV use was as a rescue mode in patients at high risk of being intubated, our conclusions are promising. Another limitation is the retrospective nature of the study that inherently leads to the risk of missed data, evident by the lack of proper documentation of oxygenation requirements and CO 2 levels in many of the instances of NIHFV use. Also, there remains a risk of selection bias in that more unstable patients may have been tried on NIHFV, and the benefit of NIHFV may be overestimated. Lastly, the lack of a control group meant study was not powered to look specifically at complications that may have arisen from NIHFV, or may not have been adequately documented. Despite some limitations, this retrospective review demonstrates that NIHFV can prevent intubation in a significant proportion of high-risk patients after other noninvasive modes of ventilation have failed. To provide definitive answers regarding the role of NIHFV in neonatal intensive care including indications, parameters of settings and its safety profile, rigorously planned prospective trials are warranted.
